DAXOR CORP 10-Q Summary: Quarter Ended June 30, 1996
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1996, and the six months ended on that date. DAXOR Corporation operates clinical laboratories, blood banks, and semen banks, while maintaining a significant portfolio of marketable securities. The company is currently engaged in multiple legal proceedings with the New York State Department of Health regarding its licensure to operate these facilities.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1996 | Six Months Ended June 30, 1995 |
|---|---|---|
| Total Revenues | $1,458,856 | $2,333,830 |
| Operating Revenues | $431,565 | $933,593 |
| Dividend Income | $1,042,892 | $1,105,375 |
| Net Income (Loss) | $(127,060) | $868,105 |
| Net Cash from Operating Activities | $199,685 | $885,374 |
| Total Assets | $35,434,702 | $37,744,621 |
| Total Liabilities | $4,542,715 | $5,691,790 |
| Shareholders' Equity | $30,891,987 | $32,052,831 |
| Cash and Cash Equivalents | $159,799 | $1,987 |
Debt and Liquidity: Total loans payable decreased to $717,297 from $1,536,609 in the prior year. This includes $200,000 in bank loans and $516,897 in short-term margin debt secured by marketable securities. The company holds $33,754,459 in marketable securities with a net unrealized gain of $9,874,743.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 37.5% year-over-year, driven primarily by a 53.8% drop in operating revenues ($431,565 vs. $933,593).
- Profitability Shift: The company reported a net loss of $127,060 for the six months ended June 30, 1996, compared to a net income of $868,105 in the same period in 1995.
- Expense Increase: Total costs and expenses rose to $1,571,524 from $1,387,650, with Selling, General, and Administrative expenses increasing significantly to $1,121,386.
- Debt Reduction: The company repaid $900,000 of its bank loan during the period, reducing total liabilities.
Outlook, Risks, and Management Commentary
Management Commentary: Management states the company has adequate resources to develop its Blood Volume Analyzer (BVA-100) and sustain its blood bank operations. However, expanding blood banking operations on a nationwide basis would require additional capital.
Legal Risks and Contingencies: The filing details extensive litigation with the New York State Department of Health regarding the revocation and denial of licenses for clinical laboratories, blood banks, and semen banks. While some appeals have been successful (e.g., Appellate Division reversed decisions on semen bank licenses), several matters remain pending, including challenges to license revocations and defamation claims. These proceedings pose a material risk to the company's ability to operate its core facilities.
Unusual Items: The company recorded a loss of $198,375 on the sale of options and commodities for the six-month period, contrasting with a gain of $7,090 in the prior year.
Investor Verification Checklist
- Verify the current status of the pending appeals regarding the New York State Department of Health license revocations, as these directly impact operating revenue.
- Confirm the valuation and liquidity of the $33.7 million marketable securities portfolio, which constitutes the majority of assets and secures existing debt.
- Assess the sustainability of operating revenues given the 54% year-over-year decline and ongoing regulatory challenges.
- Review the terms of the $516,897 margin debt to understand potential margin call risks if the securities portfolio value declines.